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2To the Editor
We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm 
syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role 
for targeted approaches to blocking inflammatory cytokines. 
Almost 30% of COVID-19 patients develops severe acute respiratory distress syndrome 
(ARDS) with high mortality rate. (2) In those critically ill patients, there are both clinical signs and 
symptoms, as well as laboratory abnormalities, that suggest a CSS is occurring in response to the 
viral infection. (1)
In contrast with adults, pediatric patients with COVID-19 seem to have a milder clinical 
course and asymptomatic SARS-CoV-2 infections may be frequent. (3) However, albeit rarely, 
severe infections may occur even in children, with PICU admission or high-flow ventilation. In a 
recent Spanish cohort, 60% of confirmed infections in children required hospitalization. (4)
COVID-19 pediatric transmission routes include close contact with family members, 
exposure to epidemic areas, or both . The school community is a place that can rapidly enhance the 
spread of a highly infectious virus, and Italian children may have been exposed to SARS-CoV-2 
infection weeks before the school lockdown decided by the government. 
Several concerns have been raised about children with autoimmune or autoinflammatory 
conditions characterized by an increased infectious risk, due both to the immune dysregulation of 
the underlying disease or to its immunosuppressive treatment, including glucocorticoids (GCs), 
conventional disease-modifying antirheumatic drugs (cDMARDs) and biologic disease-modifying 
drugs (bDMARDs).  However, the increasing knowledge about the pathophysiology of SARS-CoV-
2 infection is paradoxically supporting the beneficial role of some well-known anti-rheumatic drugs 
for the management of severe COVID-19. (5) Preliminary experience has shown that adult patients 
with chronic arthritis treated with bDMARDs or cDMARDs do not seem to be at increased risk of 
respiratory or life-threatening complications from SARS-CoV-2 compared with the general 
population. (6) Moreover, in another recent report on  patients with Inflammatory Bowel Disease 
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3(IBD) treated with cDMARDS and or bDMARDS none of them was affected by a complicated 
SARS-CoV-2 related pneumonia. (7)
Pediatric rheumatologists are certainly involved in decisions related to chronic care and 
management during this difficult period, (8), but to the best of our knowledge there are no 
published data yet related to the risk of severe complications from SARS-CoV-2 infection in 
children affected with rheumatic diseases .  
In order to investigate the impact of COVID-19 on pediatric patients with rheumatic 
diseases treated with bDMARDs, with or without cDMARDS, a questionnaire was prepared and 
administered in our pediatric rheumatology clinics in Milan, Lombardy, the most affected region in 
Italy. The survey evaluated patients’ health conditions, direct exposure to subjects known to be 
affected by COVID-19, modifications of ongoing DMARDs treatment and potential flares of 
underlying disease during the early weeks of Italian COVID-19 outbreak. All patients had provided 
their informed consent for the use of personal and clinical data for scientific purposes, and no 
patient refused to participate.
Between 25th February and 14th April 2020, we collected data from children treated with 
bDMARDs and followed in the ASST Pini and Fondazione IRCCS Ca’ Granda Policlinico 
hospitals in Milan. The survey was administered face-to-face to all patients during outpatient clinic 
visits, or by telephone in those who missed a scheduled visit during the period under review. The 
final study population included 123 pediatric patients (83F, 62 %, median age 13 years, range 4-20) 
on bDMARDs for chronic rheumatic diseases (89 with juvenile idiopathic arthrtis, 5 with chronic 
uveitis, 5 with autoinflammatory disease, 24 with others chronic rheumatic diseases). As shown 
in Table 1, none of them were confirmed cases of COVID-19. Eight children presented mild 
respiratory symptoms, three of them were family members of adults suspected for COVID-19 
infection. In our region diagnostic swabs are not routinely performed, and a case is considered 
probable in the context of epidemic area and compatible clinical signs and symptoms (fever, cough, 
dyspnea). No patient stopped ongoing therapy or needed hospitalization. All contacted patients 
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4declared that they had adopted a preventive strategy against COVID-19 based on social distancing 
and use of personal protective equipment, even if this usually happened only after the beginning of 
the outbreak.
Our results do not allow any conclusions on the incidence rate of SARS-CoV-2 infection in 
children with rheumatic diseases, nor on the overall outcome of immunocompromised patients 
affected by COVID-19. However, according to the above mentioned observations on adult 
rheumatology patients (6), our preliminary experience supports the idea that patients with chronic 
diseases treated with bDMARDs do not seem to be at increased risk of respiratory or life-
threatening complications from SARS-CoV-2 compared with the general population. Keeping the 
disease under control may therefore be extremely important even during the epidemic, since it is 
known that disease activity may be a risk factor for superimposed infections. 
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5Table 1. 
Disease
Juvenile Idiopathic Arthritis (JIA) 89 (72.3)
   Oligoarticular 60 (48.8)
   Poliarticular (Rheumatoid Factor negative) 14 (11.4)
   Poliarticular (Rheumatoid Factor positive) 0
   Enthesitis Related Arthritis 4 (3.3)
   Systemic JIA 7 (5.7)
   Psoriatic 4 (3.3)
Autoinflammatory diseases 5 (4.1)
Cronic uveitis 5 (4.1)
Recurrent pericarditis 2 (1.6)
Others 22 (17.9)
Female 83 (62.4)
Median desease duration * 6 (3-10)
bDMARDS
Anti TNF 95 (77.2)
   Etanercept 38 (30.9)
   Adalimumab 53 (43.1)
   Infliximab 4 (3.3)
Anakinra 7 (5.7)
Tocilizumab 7 (7.7)
Canakinumab 2 (1.6)
Baricitinib 1 (0.8)
Other 11 (8.9)
Concomitant cDMARDS
Methotrexate 77 (62.7)
Colchicine 3 (2.4)
Cyclosporine 1 (0.8)
Mycophenolate mofetil 1 (0.8)
Systemic steroids 6 (4.9)
Confirmed COVID – 19 infection 0
Suspected COVID – 19 infection 0
Children with mild respiratory symptoms 8 (3 of them family members of adults suspected for COVID-19)
Principal characteristics of 123 pediatric patients with chronic rheumatic diseases on 
bDMARDS. Values are expressed in numbers (%). * median (1°-3° quartile)
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